Arman Oruc, Antitrust and Competition co-chair, joined the Bloomberg Intelligence podcast to share his views on the FTC and its impact on M&A for the pharma and biotech industry and companies' strategies.
Related Content
- InsightNovember 1, 2024
Four Steps to Maximize the Value of AI Innovation in Medtech
- InsightNovember 1, 2024
How the EU AI Act Could Affect Medtech Innovation
- Big Molecule WatchOctober 31, 2024
Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar
- Big Molecule WatchOctober 30, 2024
Bio-Thera and Gedeon Richter Reach Exclusive Commercialization Agreement for Ustekinumab Biosimilar
- AlertOctober 25, 2024
NYDFS Publishes Guidance on AI-Related Cybersecurity Risks
- Big Molecule WatchOctober 24, 2024
Accord Biopharma Announces FDA Approval of IMULDOSA (ustekinumab-srlf)
- Big Molecule WatchOctober 23, 2024
Federal Circuit Denies Injunction Pending Appeal After Amgen Beat Preliminary Injunction for Biosimilar Aflibercept
- Big Molecule WatchOctober 23, 2024
GlaxoSmithKline and Northwestern Sue Moderna for Patent Infringement in Trio of Lawsuits
- Speaking EngagementsNovember 12, 2024
US & EP Data Exclusivity: Same Name, Different Games
- Press ReleaseNovember 1, 2024
Goodwin Advises ProQR on $69.8 Million Underwritten Public Offering Closing and $12.3 Million Concurrent Private Placement
- Press ReleaseOctober 31, 2024
Aerovate Therapeutics to Combine with Jade Biosciences in All-Stock Transaction
- Press ReleaseOctober 30, 2024
Goodwin Advises Septerna in $288 Million Upsized Initial Public Offering
- Awards and RankingsOctober 30, 2024
Eight Goodwin Partners Named 2025 IAM Global Leaders
- Press ReleaseOctober 28, 2024
Goodwin Advises TELA on $46 Million Underwritten Public Offering of Common Stock
- Press Release28 October 2024
Myricx Raises £90 Million Series A
- Press ReleaseOctober 22, 2024
Joshua Zachariah Named a Law360 MVP in Mergers & Acquisitions